Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06790602 · ClinicalTrials.gov registry record · Phase 2
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase 2 study of Pancreatic Ductal Adenocarcinoma (mPDAC), sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT06790602 is a Phase 2 study of Pancreatic Ductal Adenocarcinoma (mPDAC) that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 43 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06790602, a Phase 2 study of Pancreatic Ductal Adenocarcinoma (mPDAC), is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with metastatic pancreatic ductal adenocarcinoma with SWItch/Sucrose Non-Fermentable (SWI/SNF) alterations who have already been treated with FOLFIRINOX (5-fluoruracil, leucovorin, irinotecan, oxaliplatin) or gemcitabine/nab-paclitaxel chemotherapy.
Conditions Studied
Interventions
- DRUG Cemiplimab Plus Gemcitabine
Study Locations (1)
California
- University of California, San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2026-01 |
| Est. Completion | 2029-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06790602
The ClinicalTrials.gov registry entry for NCT06790602 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma (mPDAC) appearing as the primary indexed condition, and to 1 intervention - of which Cemiplimab Plus Gemcitabine is the first listed.
NCT06790602 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06790602 about?
NCT06790602 is a clinical study titled "Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma". This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with metastatic pancreatic ductal adenocarcinoma with SWItch/Sucrose Non-Fermentable (SWI/SNF) alterations who have already been treated with FOLFIR...
What is the current status of trial NCT06790602?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2026-01. Estimated completion is 2029-12.
What conditions does trial NCT06790602 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma (mPDAC).
What interventions are being tested in trial NCT06790602?
The interventions under investigation include: Cemiplimab Plus Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT06790602?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06790602 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.